US RNA-based drug developer Sarepta Therapeutics (Nasdaq: SRPT) says it has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) to US biotech major Gilead Sciences (Nasdaq: GILD) for $125 million.
Investors were not overly impressed, with Sarepta’s shares up just 1.4% at $28.68 by close of trading yesterday following the announcement.
Sarepta received the PRV when Exondys 51 (eteplirsen)was approved by the US Food and Drug Administration for the treatment of patients with Duchenne muscular dystrophy amenable to exon 51 skipping, making it the first drug to gain FDA approval for this rare disease.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze